MENLO PARK, Calif.--(BUSINESS WIRE)--Depomed, Inc. (NASDAQ: DEPO) today announced the results of its recently completed Phase 2a pharmacokinetic / pharmacodynamic proof-of-concept study in gastroesophageal reflux disease (GERD). The study demonstrated the potential clinical advantages of the delivery of omeprazole in two evening pulses to patients suffering with nocturnal acid breakthrough (NAB) associated with GERD. Omeprazole, a proton pump inhibitor, is an FDA-approved compound for the treatment of GERD.
